Publications

Shinde P, Willemsen L, Anderson M, Aoki M, Basu S, Burel JG, Cheng P, Ghosh Dastidar S, Dunleavy A, Einav T, Forschmiedt J, Fourati S, Garcia J, Gibson W, Greenbaum JA, Guan L, Guan W, Gygi JP, Ha B, Hou J, Hsiao J, Huang Y, Jansen R, Kakoty B, Kang Z, Kobie JJ, Kojima M, Konstorum A, Lee J, Lewis SA, Li A, Lock EF, Mahita J, Mendes M, Meng H, Neher A, Nili S, Olsen LR, Orfield S, Overton JA, Pai N, Parker C, Qian B, Rasmussen M, Reyna J, Richardson E, Safo S, Sorenson J, Srinivasan A, Thrupp N, Tippalagama R, Trevizani R, Ventz S, Wang J, Wu CC, Ay F, Grant B, Kleinstein SH, Peters B
Sidney J, Kim A-R, de Vries RD, Peters B, Meade PS, Krammer F, Grifoni A, Sette A
Steele H, Willicut A, Dell G, Ghastine A, Nguyen XX, Lembicz P, Doerflein H, Suchoski T, Kato E, Feghali-Bostwick C, Croft M, Herro R
Stetsenko V, Gail DP, Reba S, Suzart VG, Sandhu AK, Sette A, Dezfulian MH, Arlehamn CSL, Carpenter SM
Jan 12, 2025

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial

Thiem VD, Anh DD, Ha VH, Van Thom N, Thang TC, Mateus J, Carreño JM, Raghunandan R, Huong NM, Mercer LD, Flores J, Escarrega EA, Raskin A, Thai DH, Van Be L, Sette A, Innis BL, Krammer F, Weiskopf D
Wang YT, Branche E, Xie J, McMillan RE, Ana-Sosa-Batiz F, Lu HH, Li QH, Clark AE, Valls Cuevas JM, Viramontes KM, Garretson AF, Dos Santos Alves RP, Heinz S, Benner C, Carlin AF, Shresta S
Willemsen L, Lee J, Shinde P, Soldevila F, Aoki M, Orfield S, Kojima M, da Silva Antunes R, Sette A, Peters B